Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery
| Status: | Terminated |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 11/10/2017 |
| Start Date: | January 2013 |
| End Date: | June 2014 |
The Effect of Standard vs Aggressive Dosing Regimens for Epsilon-aminocaproic Acid on a Quantifiable Parameter of Fibrinolysis as Measured by Thromboelastography
This study hopes to determine the optimal antifibrinolytic dosing to decrease bleeding and
blood transfusion after cardiac surgery without increasing adverse events
blood transfusion after cardiac surgery without increasing adverse events
Inclusion Criteria:
- Ability to sign informed consent
- Elective cardiac surgery patients undergoing primary surgery involving circulatory
arrest
Exclusion Criteria:
- Inability to sign informed consent
- Baseline hypercoagulable condition as defined in medical record
- Coronary disease with untreated lesions or recent coronary stent placement
- Severe renal dysfunction (ESRD) as documented in medical record
We found this trial at
1
site
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
